Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib | Zendy

Thomas J. Lynch | Zendy; Daphne W. Bell | Zendy; Raffaella Sordella | Zendy; Sarada Gurubhagavatula | Zendy; Ross A. Okimoto | Zendy; Brian W. Brannigan | Zendy; Patricia L. Harris | Zendy; Sara M. Haserlat | Zendy; Jeffrey G. Supko | Zendy; Frank G. Haluska | Zendy; David N. Louis | Zendy; David C. Christiani | Zendy; Jeff Settleman | Zendy; Daniel A. Haber | Zendy

Open Access

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Author(s) -

Thomas J. Lynch,

Daphne W. Bell,

Raffaella Sordella,

Sarada Gurubhagavatula,

Ross A. Okimoto,

Brian W. Brannigan,

Patricia L. Harris,

Sara M. Haserlat,

Jeffrey G. Supko,

Frank G. Haluska,

David N. Louis,

David C. Christiani,

Jeff Settleman,

Daniel A. Haber

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa040938

Subject(s) - gefitinib , epidermal growth factor receptor , lung cancer , cancer research , tyrosine kinase , medicine , epidermal growth factor , tyrosine kinase inhibitor , mutation , biology , cancer , receptor , gene , genetics

Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research